Sonidegib Diphosphate

磷酸索立德吉

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameSonidegib Diphosphate
Drug Alias Name索立德吉Erismodegib-phosphate索尼地吉Sonidegib-phosphate索尼德吉 +[12] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSmoothened receptor antagonists
TargetsSmoothened receptor
Therapy Area/IndicationsMetastatic breast cancerLiver DysfunctionGastroesophageal Junction Neoplasms +[47] 
Global Approved IndicationsCarcinoma, Basal Cell
Approved Indications in ChinaCarcinoma, Basal Cell
Original Approved Country/TerritoryUnited States
Original Approved Date2015/07/24
Country/TerritoryCzechiaBelgiumBulgaria +[29] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesNovartis Pharma Ag
China Registration ClassN/A

Develop Information

Active CompaniesSun Pharmaceutical Industries LtdNovartis Pharma AgSun Pharmaceutical Industries (Europe) Bv +[5] 
Inactive CompaniesDana-Farber Cancer InstituteWashington University School Of MedicineNational Cancer Institute +[9] 
Active IndicationsMultiple MyelomaCarcinoma, Basal Cell
Inactive IndicationsMetastatic breast cancerLiver DysfunctionGastroesophageal Junction Neoplasms +[45] 

Other Information

ATC CodeL01XJ02
Related LinksWikipediaDrugBankKEGG